Plant Comparison

Perforate St John’s-wort vs Lavender

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant APerforate St John’s-wortHypericum perforatumHypericaceaeFull monograph →
Plant BLavenderLavandula angustifoliaLamiaceaeFull monograph →

At a glance

Perforate St John’s-wort and Lavender: they share 7 indicated uses (arthritis / joint pain, eczema, infection (general), …); 4 pharmacological actions in common.

Perforate St John’s-wortLavender
Constituents32
Pharmacological actions67
Indicated uses910
Safety notes22
Cited sources3125
Indicated uses
Only Perforate St John’s-wort
BruisingCold & flu
Shared (7)
Arthritis / joint painEczemaInfection (general)Inflammation (general)Insomnia / sleeplessnessSkin irritationWounds
Only Lavender
Cancer (anticancer research)Menstrual crampsMuscle spasm
Pharmacological actions
Only Perforate St John’s-wort
AntiviralVulnerary (wound healing)
Shared (4)
Anti-inflammatoryAntioxidantEmollient / skin-soothingSedative / sleep support
Only Lavender
Anticancer (preclinical)AntimicrobialAntispasmodic

Evidence face-off — shared uses

ConditionPerforate St John’s-wortLavenderVerdict
Arthritis / joint pain1/105/10Stronger for Lavender
Eczema1/105/10Stronger for Lavender
Infection (general)1/105/10Stronger for Lavender
Inflammation (general)1/105/10Stronger for Lavender
Insomnia / sleeplessness1/105/10Stronger for Lavender
Skin irritation1/105/10Stronger for Lavender
Wounds1/105/10Stronger for Lavender

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Naphthodianthrones (hypericin, pseudohypericin)[4]

Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.

Phloroglucinols (hyperforin)[4]

Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.

Hyperforin
Flavonoids (hyperoside, quercetin, rutin)[4]

Antioxidant flavonoids contributing to overall activity.

FlavonoidsQuercetinRutin
Essential oil (linalool, linalyl acetate)[4]

Flower essential oil dominated by linalool and linalyl acetate, the principal compounds behind the calming, anxiolytic and antimicrobial activity.

Essential (volatile) oilLinalool
Flavonoids and phenolic acids

Antioxidant constituents of the flower.

FlavonoidsPhenolic acids

Pharmacological Actions

Anti-inflammatory[5, 15, 16]
Antioxidant[6, 15, 16]
Antiviral[15, 16]
Emollient / skin-soothing[15, 16]
Sedative / sleep support[1, 2, 4, 5, 9, 11, 12, 13, 14, 15, 16]
Vulnerary (wound healing)[4, 15, 16]
Anti-inflammatory[4, 12, 16, 17, 18]
Anticancer (preclinical)[13]
Antimicrobial[6, 16, 17, 18]
Antioxidant[10, 16, 17, 18]
Antispasmodic[16, 17, 18]

Antispasmodic (cramp easing)

Emollient / skin-soothing[16, 17, 18]
Sedative / sleep support[5, 7, 8, 9, 11, 14, 16, 17, 18]

Traditional & Indicated Uses

Arthritis / joint pain[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Bruising[15, 16]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Bruising
Cold & flu[15, 16]Traditional · 1/10

inferred from antiviral action

Evidence: 1
Label: Cold & flu
Eczema[15, 16]Traditional · 1/10

inferred from emollient action

Evidence: 1
Label: Eczema
Infection (general)[15, 16]Traditional · 1/10

inferred from antiviral action

Evidence: 1
Label: Infection (general)
Inflammation (general)[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Insomnia / sleeplessness[15, 16]Traditional · 1/10

inferred from sedative action

Evidence: 1
Label: Insomnia / sleeplessness
Skin irritation[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Wounds[15, 16]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Wounds
Arthritis / joint pain[16, 17, 18]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Arthritis / joint pain
Cancer (anticancer research)[13]Traditional · 2/10

inferred from anticancer action

Evidence: 2
Label: Cancer (anticancer research)
Eczema[16, 17, 18]Moderate · 5/10

inferred from emollient action

Evidence: 5
Label: Eczema
Infection (general)[16, 17, 18]Moderate · 5/10

inferred from antimicrobial action

Evidence: 5
Label: Infection (general)
Inflammation (general)[16, 17, 18]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Inflammation (general)
Insomnia / sleeplessness[16, 17, 18]Moderate · 5/10

inferred from sedative action

Evidence: 5
Label: Insomnia / sleeplessness
Menstrual cramps[16, 17, 18]Moderate · 5/10

inferred from antispasmodic action

Evidence: 5
Label: Menstrual cramps
Muscle spasm[16, 17, 18]Moderate · 5/10

inferred from antispasmodic action

Evidence: 5
Label: Muscle spasm
Skin irritation[16, 17, 18]Moderate · 5/10

inferred from anti-inflammatory action

Evidence: 5
Label: Skin irritation
Wounds[16, 17, 18]Moderate · 5/10

inferred from antimicrobial action

Evidence: 5
Label: Wounds

Safety, Cautions & Contraindications

Safety note[15, 16]Caution

Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.

Safety note[15, 16, 17]Caution

Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).

Safety note[16, 17, 18]Caution

Generally very safe. Essential oil should not be ingested in large amounts. Rarely, contact dermatitis may occur. May potentiate the effect of sedative medications. Avoid therapeutic doses during pregnancy.

Safety note[16, 17, 18, 19]Info

Duke (2002) rates lavender as ++ and provides clinical evidence (score 2) for carminative activity, consistent with Commission E approval for nervous stomach disorders and functional abdominal complaints. Additional experimental activities include anxiolytic, antispasmodic, and antiseptic effects. The essential oil demonstrates COX-2 inhibitory and Alzheimer's-relevant properties at the experimental level. Dose: 1–2 teaspoons (4–8 g) dried flowers as tea; 1–3 drops essential oil in a carrier for topical or aromatherapy use. Duke notes that oral lavender oil (Silexan) has clinical evidence for generalized anxiety disorder (Duke, 2002).

External Ids

Gbif: 3189486
Powo: urn:lsid:ipni.org:names:433719-1
Wikidata: Q158289
Gbif: 2927305
Wikidata: Q42081

Botanical Description

Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]

Height: 30-90 cm
Habit: Erect, branching perennial herb
Leaves: Paired, oval, dotted with tiny translucent oil glands
Flowers: Bright yellow, five-petalled, with numerous stamens and black-dotted petal edges, in flat-topped clusters
Stem: Erect, branching, with two raised longitudinal ridges
Root: Woody rootstock with spreading rhizomes
Fruit: Small, three-valved capsule
Flowering Period: June-September (traditionally around St John's Day, 24 June)

Aromatic, evergreen, woody-based perennial subshrub with narrow, grey-green, felted leaves. Slender flowering spikes carrying whorls of small, tubular, two-lipped violet-blue flowers rise well above the foliage on long, unbranched stalks.[4]

Height: 30-60 cm
Habit: Aromatic, evergreen, woody-based perennial subshrub
Leaves: Narrow, grey-green, felted
Flowers: Small, tubular, two-lipped, violet-blue, in whorled spikes on long stalks
Stem: Woody at the base, with slender unbranched flowering stalks
Root: Woody rootstock
Fruit: Small nutlet (typical of Lamiaceae)
Flowering Period: June-August

Habitat

Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]

Native to the mountains of the western Mediterranean (southern France, Spain, Italy); widely cultivated in sunny, well-drained, often calcareous sites across temperate and Mediterranean climates worldwide.[4]

Harvesting

The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]

Parts: Flower, Leaf
Season: Summer, at flowering

The flower spikes are cut as the flowers open, in mid- to late summer, when essential oil content is highest, and dried in a warm, shaded, airy place or distilled fresh for essential oil.[4]

Parts: Flower
Season: Mid- to late summer, at flowering

Traditional Uses

St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]

Lavender flower has a long Mediterranean and European tradition as a calming, sedative herb for nervous tension, anxiety and insomnia, and as a mild digestive carminative and antiseptic for minor wounds and skin irritation; the essential oil in particular has an extensive modern clinical evidence base for anxiety and sleep support.[4]

Preparations

Standardised extract[1]

Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.

Infusion[4]

Dried flowers infused in hot water as a traditional calming, digestive tea.

Essential oil (aromatherapy/topical)[4]

Steam-distilled from the flowers; used diluted topically or by inhalation for relaxation and skin care.

Dosage

Standardised extract[1]

Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.

Infusion[15]

The EU herbal monograph gives 1-2 g of the flower in 150 mL of boiling water as an infusion, three times daily, in adolescents, adults and elderly; a tincture at 2-4 mL three times daily is also listed. The monograph notes that lavender may impair the ability to drive or use machines. Not recommended under 12 years. Educational reference only, not a prescription.

Drug Class Interactions

Safety note[18, 19, 20, 21]Avoid
Drug Class: antidepressants-serotonergic
Mechanism: St John's wort raises serotonin activity; combined with SSRIs, SNRIs or MAOIs it can trigger serotonin syndrome (agitation, tremor, sweating, rapid heartbeat). Reviews of clinical reports document serotonin syndrome and lethargy when it is combined with serotonin-reuptake inhibitors.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 22]Avoid
Drug Class: antiretrovirals
Mechanism: Potent CYP3A4 and P-glycoprotein induction lowers antiretroviral levels (indinavir exposure fell ~57%), risking loss of viral control and drug resistance.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 23]Avoid
Drug Class: immunosuppressants
Mechanism: Enzyme and transporter induction reduces ciclosporin and tacrolimus levels; reported to cause subtherapeutic concentrations and transplant rejection.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 24, 25, 26]Avoid
Drug Class: hormonal-therapies
Mechanism: Increased metabolism of ethinylestradiol and progestins reduces contraceptive exposure, causing breakthrough bleeding, ovulation and unplanned pregnancy. Randomised and controlled trials in women confirmed more breakthrough bleeding, reduced progestin levels and evidence of ovulation when St John's wort was added to the pill.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: anticoagulants-antiplatelets
Mechanism: CYP induction increases warfarin clearance and can lower INR, reducing the anticoagulant effect; close monitoring is needed.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 27]Caution
Drug Class: cardiac-glycosides
Mechanism: P-glycoprotein induction lowers digoxin levels (AUC fell ~25% over ten days), which may reduce its effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: statins
Mechanism: CYP3A4 induction lowers levels of simvastatin and atorvastatin, potentially weakening their cholesterol-lowering effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: cyp3a4-substrates
Mechanism: As a broad CYP3A4 and P-glycoprotein inducer, St John's wort can lower levels of many medicines cleared by this pathway; check each medication individually.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[20, 28, 29]Avoid
Drug Class: chemotherapy-agents
Mechanism: St John's wort strongly induces CYP3A4 and P-glycoprotein, speeding the breakdown and removal of several cancer medicines. In patients it cut the active form of irinotecan (SN-38) by about 42% and reduced imatinib exposure by roughly a third - enough to weaken treatment and risk drug resistance. Do not take St John's wort during chemotherapy.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[20, 21, 22]Caution
Drug Class: sedatives-cns-depressants
Mechanism: Lavender has calming, sedative effects (its anxiolytic effect is supported by a meta-analysis of randomised trials of the oral oil preparation Silexan); taken with sedatives, sleeping tablets or other central-nervous-system depressants (including alcohol) it may add to drowsiness and slowed reactions.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

References

REF-0842, REF-0843, REF-0844, REF-1789, REF-1790, REF-1791, REF-1792, REF-1793, REF-1794, REF-1795, REF-1796, REF-1797, REF-1798, REF-1799
REF-0857, REF-0858, REF-0859, REF-2205, REF-2206, REF-2207, REF-2208, REF-2209, REF-2210, REF-2211, REF-2212, REF-2213, REF-2214, REF-2215

Pairings

St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]

Partner Id: crocus-sativus
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]

Partner Id: rhodiola-rosea
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]

Partner Id: valeriana-officinalis
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]

Partner Id: piper-methysticum
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Lavender and valerian are both calming herbs used to aid relaxation and sleep; taken together their sedative effects can add up, so while they may help relaxation they can also increase drowsiness — avoid combining with sedative medicines or before driving.[22, 23]

Partner Id: valeriana-officinalis
Type: synergy
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Lavender and lemon balm are both calming herbs used to ease anxiety and aid sleep; taken together their sedative effects can add up, so while they may help relaxation they can also increase drowsiness — avoid combining with sedative medicines or before driving.[22, 24]

Partner Id: melissa-officinalis
Type: synergy
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Lavender and chamomile are both calming herbs used to ease anxiety and aid sleep; taken together their sedative effects can add up, so while they may help relaxation they can also increase drowsiness — avoid combining with sedative medicines or before driving.[22, 25]

Partner Id: matricaria-chamomilla
Type: synergy
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

References & Sources

  1. Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
    https://doi.org/10.1016/j.jad.2016.12.048
  2. Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
    https://doi.org/10.1007/s00210-022-02229-z
  3. Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
    https://doi.org/10.1016/S0140-6736(99)06457-0
  4. Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
    https://doi.org/10.22038/IJBMS.2022.65112.14338
  5. Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
    https://doi.org/10.1016/j.phymed.2024.155847
  6. Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
    https://doi.org/10.3389/fpls.2016.01004
  7. Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
    https://doi.org/10.1002/ptr.5050
  8. Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
    https://doi.org/10.1016/j.jep.2010.07.034
  9. Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
    https://doi.org/10.1016/j.lfs.2004.04.005
  10. Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
    https://doi.org/10.3109/13697137.2013.861814
  11. Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
    https://doi.org/10.2165/00003088-200645050-00002
  12. Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
    https://doi.org/10.1055/s-2001-15467
  13. Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
    https://doi.org/10.1038/sj.mp.4000557
  14. Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
    https://doi.org/10.2174/1568026033392589
  15. Linde, K. et al (2008) 'St John'. Traditional / reference
    https://scholar.google.com/scholar?q=St%20John
  16. Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
    https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St
  17. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  18. Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
    https://doi.org/10.1177/0269881104042632
  19. Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
    https://doi.org/10.2165/11317010-000000000-00000
  20. Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
    https://doi.org/10.1208/s12248-009-9146-8
  21. Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
    https://doi.org/10.1111/bph.14936
  22. Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
    https://doi.org/10.1016/S0140-6736(99)05712-8
  23. Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
    https://doi.org/10.1345/aph.10088
  24. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  25. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  26. Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
    https://doi.org/10.1046/j.1365-2125.2003.02005.x
  27. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
    https://doi.org/10.1053/cp.1999.v66.a101944
  28. Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
    https://doi.org/10.1093/jnci/94.16.1247
  29. Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
    https://doi.org/10.1592/phco.24.16.1508.50958
  30. Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
    https://doi.org/10.5414/cpp42139
  31. Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
    https://doi.org/10.3390/ph19030399
  1. Tan, L., Liao, F.F., Long, L.Z., Ma, X.C. et al (2023) 'Essential oils for treating anxiety: a systematic review of randomized controlled trials and network meta-analysis', Frontiers in Public Health, 11, pp. 1144404. doi:10.3389/fpubh.2023.1144404 Meta-analysis / review
    https://doi.org/10.3389/fpubh.2023.1144404
  2. Dos Reis Lucena, L., Dos Santos-Junior, J.G., Tufik, S. and Hachul, H (2021) 'Lavender essential oil on postmenopausal women with insomnia: Double-blind randomized trial', Complementary Therapies in Medicine, 59, pp. 102726. doi:10.1016/j.ctim.2021.102726 Randomized trial
    https://doi.org/10.1016/j.ctim.2021.102726
  3. Moss, M., Cook, J., Wesnes, K. and Duckett, P (2003) 'Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults', International Journal of Neuroscience, 113(1), pp. 15-38. doi:10.1080/00207450390161903 Randomized trial
    https://doi.org/10.1080/00207450390161903
  4. Denner, S.S (2009) 'Lavandula angustifolia Miller: English lavender', Holistic Nursing Practice, 23(1), pp. 57-64. doi:10.1097/01.HNP.0000343210.56710.fc Meta-analysis / review
    https://doi.org/10.1097/01.HNP.0000343210.56710.fc
  5. Basch, E., Foppa, I., Liebowitz, R., Nelson, J., Smith, M., Sollars, D. and Ulbricht, C (2004) 'Lavender (Lavandula angustifolia Miller)', Journal of Herbal Pharmacotherapy, 4(2), pp. 63-78. doi:10.1080/j157v04n02_07 Meta-analysis / review
    https://doi.org/10.1080/j157v04n02_07
  6. Betlej, I., Andres, B., Cebulak, T., Kapusta, I., Balawejder, M., Zurek, N., Jaworski, S., Lange, A., Kutwin, M., Pisulewska, E., Kidacka, A., Krochmal-Marczak, B., Boruszewski, P. and Borysiuk, P (2024) 'Phytochemical composition and antimicrobial properties of new Lavandula angustifolia ecotypes', Molecules, 29(8), pp. 1740. doi:10.3390/molecules29081740 Preclinical
    https://doi.org/10.3390/molecules29081740
  7. Rahimian, Z., Sadrian, S., Shahisavandi, M., Aligholi, H., Zarshenas, M.M., Abyar, A., Zeraatpisheh, Z. and Asadi-Pooya, A.A (2023) 'Antiseizure effects of Lavandula angustifolia L', BioMed Research International, 2023, pp. 4121998. doi:10.1155/2023/4121998 Preclinical
    https://doi.org/10.1155/2023/4121998
  8. de Melo Alves Silva, L.C., de Oliveira Mendes, F.D.C., de Castro Teixeira, F., de Lima Fernandes, T.E., Barros Ribeiro, K.R., da Silva Leal, K.C., Dantas, D.V. and Neves Dantas, R.A (2023) 'Use of Lavandula angustifolia essential oil as a complementary therapy in adult health care: a scoping review', Heliyon, 9(5), pp. e15446. doi:10.1016/j.heliyon.2023.e15446 Meta-analysis / review
    https://doi.org/10.1016/j.heliyon.2023.e15446
  9. Lejeune, V.B.P., Lopes, R.V., Baggio, D.F., Koren, L.D.O., Zanoveli, J.M. and Chichorro, J.G (2023) 'Antinociceptive and anxiolytic-like effects of Lavandula angustifolia essential oil on rat models of orofacial pain', Journal of Applied Oral Science, 30, pp. e20220304. doi:10.1590/1678-7757-2002-0304 Preclinical
    https://doi.org/10.1590/1678-7757-2002-0304
  10. Mykhailenko, O., Hurina, V., Ivanauskas, L., Marksa, M., Skybitska, M., Kovalenko, O., Lytkin, D., Vladymyrova, I. and Georgiyants, V (2024) 'Lavandula angustifolia herb from Ukraine: comparative chemical profile and in vitro antioxidant activity', Chemistry & Biodiversity, 21(9), pp. e202400640. doi:10.1002/cbdv.202400640 Preclinical
    https://doi.org/10.1002/cbdv.202400640
  11. Shamabadi, A. and Akhondzadeh, S (2021) 'Efficacy and tolerability of Lavandula angustifolia in treating patients with the diagnosis of depression: a systematic review of randomized controlled trials', Journal of Complementary & Integrative Medicine, 20(1), pp. 81-91. doi:10.1515/jcim-2020-0498 Meta-analysis / review
    https://doi.org/10.1515/jcim-2020-0498
  12. Cardia, G.F.E., Silva-Filho, S.E., Silva, E.L., Uchida, N.S., Cavalcante, H.A.O., Cassarotti, L.L., Salvadego, V.E.C., Spironello, R.A., Bersani-Amado, C.A. and Cuman, R.K.N (2018) 'Effect of lavender (Lavandula angustifolia) essential oil on acute inflammatory response', Evidence-Based Complementary and Alternative Medicine, 2018, pp. 1413940. doi:10.1155/2018/1413940 Preclinical
    https://doi.org/10.1155/2018/1413940
  13. Aboalhaija, N.H., Syaj, H., Afifi, F., Sunoqrot, S., Al-Shalabi, E. and Talib, W (2022) 'Chemical evaluation, in vitro and in vivo anticancer activity of Lavandula angustifolia grown in Jordan', Molecules, 27(18), pp. 5910. doi:10.3390/molecules27185910 Preclinical
    https://doi.org/10.3390/molecules27185910
  14. Caputo, L., Reguilon, M.D., Minarro, J., De Feo, V. and Rodriguez-Arias, M (2018) 'Lavandula angustifolia essential oil and linalool counteract social aversion induced by social defeat', Molecules, 23(10), pp. 2694. doi:10.3390/molecules23102694 Preclinical
    https://doi.org/10.3390/molecules23102694
  15. European Medicines Agency (HMPC) (2012) 'Community herbal monograph on Lavandula angustifolia Miller, flos'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-lavandula-angustifolia-p-mill-flos_en.pdf Traditional / reference
    https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-lavandula-angustifolia-p-mill-flos_en.pdf
  16. Cavanagh, H.M.A. and Wilkinson, J.M (2002) 'Biological activities of lavender essential oil', 16(4), pp. 301--308. doi:10.1002/ptr.1103 Traditional / reference
    https://doi.org/10.1002/ptr.1103
  17. Lis-Balchin, M (2002) 'Lavender: The Genus Lavandula'. Traditional / reference
    https://scholar.google.com/scholar?q=Lavender%3A%20The%20Genus%20Lavandula
  18. Schuwald, A.M. et al (2013) 'Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels', 8(4). doi:10.1371/journal.pone.0059998 Randomized trial
    https://doi.org/10.1371/journal.pone.0059998
  19. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  20. Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
    https://doi.org/10.1002/ptr.8201
  21. Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
    https://doi.org/10.1177/1534735404265003
  22. Dold, M., Bartova, L., Volz, H.P., Seifritz, E., Moller, H.J., Schlafke, S. and Kasper, S (2023) 'Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials', European Archives of Psychiatry and Clinical Neuroscience, 273(7), pp. 1615-1628. doi:10.1007/s00406-022-01547-w Meta-analysis / review
    https://doi.org/10.1007/s00406-022-01547-w
  23. Bent, S., Padula, A., Moore, D., Patterson, M. and Mehling, W (2006) 'Valerian for sleep: a systematic review and meta-analysis', The American Journal of Medicine, 119(12), pp. 1005-1012. doi:10.1016/j.amjmed.2006.02.026 Meta-analysis / review
    https://doi.org/10.1016/j.amjmed.2006.02.026
  24. Haybar, H., Javid, A.Z., Haghighizadeh, M.H., Valizadeh, E., Mohaghegh, S.M. and Mohammadzadeh, A (2018) 'The effects of Melissa officinalis supplementation on depression, anxiety, stress, and sleep disorder in patients with chronic stable angina', Clinical Nutrition ESPEN, 26, pp. 47-52. doi:10.1016/j.clnesp.2018.04.015 Randomized trial
    https://doi.org/10.1016/j.clnesp.2018.04.015
  25. Amsterdam, J.D., Li, Y., Soeller, I., Rockwell, K., Mao, J.J. and Shults, J (2009) 'A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder', Journal of Clinical Psychopharmacology, 29(4), pp. 378-382. doi:10.1097/JCP.0b013e3181ac935c Randomized trial
    https://doi.org/10.1097/JCP.0b013e3181ac935c

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.